GS-441524 is an adenosine analog and the parent nucleoside of the prodrug remdesivir,
which has received emergency approval for treatment of COVID-19. Recently, GS-441524 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the
COVID-19 pandemic, has infected over 260 million people over the past 2 years. Remdesivir …

GS‐441524, the parent nucleoside of remdesivir, has been proposed to be effective against
Covid‐19 based on in vitro studies and studies in animals. However, randomized clinical …

Despite being FDA-approved for COVID-19, the clinical efficacy of remdesivir (Veklury®)
remains contentious. We previously pointed out pharmacokinetic, pharmacodynamic and …

GS-441524 is a nucleoside analogue with broad-spectrum antiviral activity against RNA
viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe …

The nucleoside metabolite of remdesivir, GS-441524 displays potent anti-SARS-CoV-2
efficacy, and is being evaluated in clinical as an oral antiviral therapeutic for COVID-19 …

While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent
nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir …

Remdesivir, a monophosphate prodrug of nucleoside analog GS-441524, is widely used for
the treatment of moderate to severe COVID-19. It has been suggested to use GS-441524 …

Remdesivir is an antiviral approved for COVID-19 treatment, but its wider use is limited by
intravenous delivery. An orally bioavailable remdesivir analog may boost therapeutic benefit …

Comprehensive Summary Supporting Clinical Investigation of GS-441524 for Covid-19
Treatment Page 1 Comprehensive Summary Supporting Clinical Investigation of GS-441524 for …